Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.81 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306510 | 0.95 | PARP1 (0.90) | PARP1PIM1CSNK1DKMT2A | |
| SCHEMBL61598 | 0.90 | PARP1 (0.82) | PARP1PIM1CSNK1DKMT2AHTR1A | |
| SCHEMBL61589 | 0.90 | PIM1 (0.85) | PARP1PIM1CSNK1DKMT2A | |
| SCHEMBL51064 | 0.90 | PIM1 (1.00) | PARP1PIM1CSNK1D | |
| SCHEMBL29496129 | 0.90 | PIM1 (1.00) | PARP1PIM1CSNK1D | |
| SCHEMBL1319786 | 0.89 | PIM1 (0.84) | PARP1PIM1CSNK1D | |
| SCHEMBL52020 | 0.89 | PARP1 (0.79) | PARP1PIM1CSNK1D | |
| SCHEMBL10035767 | 0.88 | PIM1 (0.82) | PARP1PIM1CSNK1DKMT2A | |
| SCHEMBL51776 | 0.88 | PIM1 (0.82) | PARP1PIM1CSNK1DKMT2A | |
| SCHEMBL51663 | 0.88 | PIM1 (0.85) | PARP1PIM1CSNK1DKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883787-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883787-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883787-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130345225-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8470825-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470825-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470825-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120115873-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | MGI GP, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090028815-A1 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp | MGI GP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090028815-A1 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp | MGI GP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090028815-A1 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp | MGI GP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-7456178-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456178-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1841771-A4 | DIAZABENZO[DE]ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | MGI GP INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1841771-A2 | DIAZABENZOÝDE¨ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | MGI GP, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006078711-A2 | DIAZABENZO[DE]ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | MGI GP, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2004105700-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | GUILDFORD PHARMACEUTICALS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115873-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PARP1 1/4885PIM1 745/4885CSNK1D 3002/4885 |
| US-20090028815-A1 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp | PARP1, PARP2, PARP3 | PARP1 1/4885PIM1 622/4885CSNK1D 3185/4885 |
| US-20130345225-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PARP1 1/4885PIM1 622/4885CSNK1D 3185/4885 |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PARP1 1/4885PIM1 1069/4885CSNK1D 2130/4885 |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | PARP1, PARP2, PARP11 | PARP1 1/4885PIM1 346/4885CSNK1D 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.